Abstract: The present invention relates to a compound of formula (I) as PARC inhibitors for the treatment of proliferative disorders, such as e.g. cancer. Preferred compounds are e.g. N,N-dimethyl-4-(7-(N-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl) piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives, such as e.g. the present example 1, N,N-dimethyl-4-(7-(N-(1-methyl-cyclopropyl)sulfamoyl)-1-(6-methylpyridin-3-yl)imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide (II). Experimental data of PARC inhibition assays of exemplary compounds is provided.

Abstract: The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form, pharmaceutically acceptable salt or a prodrug thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. Instant compounds are particularly useful as PARC inhibitors, and can be used in a method of treatment of a proliferative disorder, preferably of cancer.

Abstract: The present invention is concerned with anticoagulants (i.e. substances that stop blood from clotting). More specifically, the present invention is concerned with orally available antithrombic oligosaccharides.